Nuvo Pharmaceuticals, a Canadian-based health care company specializing in pain management, dermatology and allergy, announced that, effective immediately, it will begin doing business as Miravo Healthcare.
"We are excited for the future as Miravo Healthcare," said Jesse Ledger, Miravo's president and CEO. "The corporate rebranding reflects Nuvo's evolution into a growing, multi-asset company, which was transformed by the acquisition of the Aralez Pharmaceuticals Canada business at the end of 2018. Miravo consolidates the Nuvo and Aralez brands under one common name. As Miravo, we will continue to focus on expanding our Canadian and international businesses through organic growth of our core Canadian products—Blexten, Cambia and Suvexx, targeted in-licensing and acquisition opportunities to further build out our product pipeline and out-licensing of distribution rights for our proprietary products—Pennsaid 2%, Resultz, Suvexx and Yosprala."